---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-029646"
form_type: "8-K"
ticker: null
cik: "0001835416"
company_name: "Moringa Acquisition Corp"
filed_at: "2024-04-03T23:59:59+00:00"
generated_at: "2026-06-04T02:56:44.831831+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Moringa restructures Silexion business combination at $62.5M valuation; new public entity Biomotion Sciences

## Summary
- A&R BCA inserts Biomotion Sciences as new public TopCo; Moringa and Silexion to become subsidiaries.
- Pre-transaction equity value of Silexion remains $62.5M ($10/share).
- SPAC sponsor must forfeit 2.875M founder shares and invest at least $350k in TopCo.
- Silexion must raise at least $3.5M by April 30, 2024; deal can be terminated if not met.
- Termination date August 19, 2024; no termination fees.

## SEC filing metadata
- accession: 0001213900-24-029646
- form_type: 8-K
- cik: 0001835416
- company_name: Moringa Acquisition Corp
- filed_at: 2024-04-03T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835416/000121390024029646/0001213900-24-029646-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835416/000121390024029646/ea0203204-8k_moringa.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-029646
- JSON: https://secwatch.observer/filing/0001213900-24-029646.json
- Plain text: https://secwatch.observer/filing/0001213900-24-029646.txt

## Key facts
- Material Agreements
  Moringa Acquisition Corp amended Amended and Restated Business Combination Agreement with Silexion Therapeutics Ltd. valued at pre-transaction equity value of $62.5 million, based on a $10 price per share (effective 2024-04-03).
  - Action: amendment
  - Agreement: merger
  - Counterparty: Silexion Therapeutics Ltd.
  - Value: pre-transaction equity value of $62.5 million, based on a $10 price per share
  - Effective: 2024-04-03
  source text: On April 3, 2024, Moringa and Silexion restructured the transactions contemplated under the Original BCA by entering into an amended and restated business combination agreement (as the same may be amended, supplemented or otherwise modified from time to time, the " Silexion Business Combination Agreement " or the " A&R BCA " ) by and among Biomotion Sciences, a Cayman Islands exempted company (" Biomotion Sciences " or " TopCo "), August M.S. Ltd., an Israeli company and a wholly owned subsidiary of TopCo (" Merger Sub 1 "), Moringa Acquisition Merger Sub Corp, a Cayman Islands exempted company and a wholly owned subsidiary of TopCo (" Merger Sub 2 "), Moringa and Silexion.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835416/000121390024029646/0001213900-24-029646-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.